Abliva AB Interim Report January – June 2024
FALCON Positioned for Success Following Analysis by Independent Committee ⎮ Strong Safety Profile Confirmed, and Both Primary Endpoints Passed Futility
Press releases
Abliva AB Publishes 2023 Annual Report
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the English version of the Annual ...
Abliva AB Interim Report January – June 2023
The first patient was dosed in the FALCON study ⎮ Orphan Drug Designation for NV354
Abliva AB Publishes 2022 Annual Report
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the English version ...
Abliva AB Interim Report January – June 2022
SEK 200 million financing secured ⎮ KL1333 study due to start this year ⎮ NV354 is being prepared for clinical studies
Abliva AB publishes 2021 Annual report
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the English version ...
Abliva AB Interim Report January – June 2021
Second quarter summary
Abliva AB publishes 2020 Annual report
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the English version of the Annual report for 2020 is now available on the company’s website, www.abliva.com.
Abliva AB Interim Report January – June 2020
NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner
NeuroVive Pharmaceutical AB publishes 2019 Annual report
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today announced that the English version of the Annual report for 2019 is now available on the company’s website, www.neurovive.com.
NeuroVive Pharmaceutical AB Interim Report January – June 2019
Focus on genetic mitochondrial diseases
NeuroVive Pharmaceutical AB Interim report January – June 2018
NeuroVive out-licenses targeted LHON therapy to BridgeBio